Biomarkers

Global Biomarkers Market to Reach US$235.2 Billion by 2030

The global market for Biomarkers estimated at US$108.7 Billion in the year 2024, is expected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.7% over the analysis period 2024-2030. Safety, one of the segments analyzed in the report, is expected to record a 13.9% CAGR and reach US$89.8 Billion by the end of the analysis period. Growth in the Efficacy segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$27.7 Billion While China is Forecast to Grow at 17.8% CAGR

The Biomarkers market in the U.S. is estimated at US$27.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$57.8 Billion by the year 2030 trailing a CAGR of 17.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.4% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Biomarkers - Key Trends and Drivers Summarized

Biomarkers have revolutionized healthcare by providing precise tools for disease identification and management, enhancing treatment efficacy, and fostering the development of new drugs. These biological indicators are measurable signals of various biological states or conditions, crucial for diagnosing diseases and monitoring the effectiveness of treatments. Initially, disease detection relied heavily on observable physical symptoms and sample analysis. However, with significant technological advancements over the years, the discovery and development of numerous biomarkers have greatly enriched medical diagnostics and treatment options. This evolution has facilitated earlier and more precise diagnoses, improved treatment strategies, and minimized errors, leading to better and more cost-effective healthcare solutions.

The integration of biomarkers into modern medicine spans various functions, from diagnosing conditions to predicting treatment outcomes. They are classified into categories such as molecular, radiographic, histologic, and physiologic biomarkers, each serving unique roles. For example, molecular biomarkers are found in biological samples like blood and cerebrospinal fluid, indicating molecular interactions and biochemical changes. Radiographic biomarkers, derived from imaging studies, non-invasively assess health conditions, such as bone density. Histologic biomarkers reflect biochemical changes in tissues or cells, crucial for diagnosing and staging cancers. Physiologic biomarkers, like blood pressure or heart rate, provide direct insights into bodily functions. These biomarkers enhance disease management through various stages of healthcare, including diagnostic, prognostic, predictive, and monitoring biomarkers, thereby optimizing patient care and treatment strategies.

The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.

SCOPE OF STUDY:

The report analyzes the Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Safety, Efficacy, Validation); Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Diseases); Application (Drug Discovery & Development, Diagnostics, Personalized Medicines, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 282 Featured) -

• Abbott Molecular, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• QIAGEN NV
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.